BRIEF published on 01/01/2026 at 07:35, 2 months 21 days ago Evotec Appoints Dr. Sarah Fakih as EVP of Global Communications and Investor Relations Investor Relations Leadership Communications Evotec Sarah Fakih
PRESS RELEASE published on 01/01/2026 at 07:30, 2 months 21 days ago Evotec appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations Evotec appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations to strengthen strategic messaging and stakeholder alignment Investor Relations Appointment Evotec Global Communications Dr. Sarah Fakih
BRIEF published on 12/08/2025 at 07:05, 3 months 14 days ago Evotec Finalizes Sale of Toulouse Site to Sandoz for $350 Million Revenue Growth Biosimilars Evotec Sandoz Technology License
BRIEF published on 12/08/2025 at 07:05, 3 months 14 days ago Evotec finalise la vente de son site de Toulouse à Sandoz pour 350 millions de dollars. Croissance Des Revenus Licence Technologique Evotec Biosimilaires Sandoz
PRESS RELEASE published on 12/08/2025 at 07:00, 3 months 14 days ago Evotec closes sale of Just – Evotec Biologics’ Toulouse site to Sandoz Evotec closes sale of Just - Evotec Biologics' Toulouse site to Sandoz for over US$650m, including technology license fees. Sale improves revenue mix and profit margins Technology Sale Evotec Sandoz Biologics
BRIEF published on 12/04/2025 at 08:35, 3 months 18 days ago Bayer Initiates Phase 2 Study for Alport Syndrome Treatment with Evotec Clinical Trial Bayer Evotec Alport Syndrome Semaphorin-3A
BRIEF published on 12/04/2025 at 08:35, 3 months 18 days ago Bayer lance une étude de phase 2 pour le traitement du syndrome d'Alport avec Evotec Bayer Essai Clinique Evotec Syndrome D'Alport Sémaphorine-3A
PRESS RELEASE published on 12/04/2025 at 08:30, 3 months 18 days ago Evotec-partner Bayer starts Phase 2 study for treatment of patients with Alport syndrome Evotec-partner Bayer initiates Phase 2 study for potential Alport syndrome treatment. BAY 3401016 mAb targets Sema3A protein Bayer Evotec Phase 2 Study Alport Syndrome BAY 3401016
BRIEF published on 11/12/2025 at 07:35, 4 months 10 days ago Evotec obtient un paiement d'étape de Bristol Myers Squibb Evotec Approbation De La FDA Paiement D'étape Bristol Myers Squibb Dégradation Des Protéines
BRIEF published on 11/12/2025 at 07:35, 4 months 10 days ago Evotec Secures Milestone Payment from Bristol Myers Squibb FDA Approval Evotec Milestone Payment Bristol Myers Squibb Protein Degradation
Published on 03/20/2026 at 13:30, 2 days 5 hours ago Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/20/2026 at 12:30, 2 days 6 hours ago CANEX Metals Announces the Numbers of Gold Basin Shares Taken up by Canex Metals
Published on 03/22/2026 at 12:23, 7 hours 6 minutes ago Borussia Dortmund and Sebastian Kehl are ending their collaboration with immediate effect
Published on 03/20/2026 at 22:45, 1 day 20 hours ago Investor Alert: Berger Montague (Canada) PC represents investors that purchased shares of Super Micro Computer, Inc. listed on the CBOE Canada and elsewhere
Published on 03/20/2026 at 21:05, 1 day 22 hours ago Fractal EMS Receives ISO/IEC 9001 and 27001 Certifications
Published on 03/20/2026 at 21:05, 1 day 22 hours ago Nebius Group announces closing of private offering of convertible senior notes, with aggregate gross proceeds of approximately $4.3 billion
Published on 03/20/2026 at 19:00, 2 days ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days ago AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 1 hour ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 1 hour ago Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA
